APA (7th ed.) Citation

N, J., S, P., M, C., W, C., B, H., AO, Y., . . . L, E. (2023). 177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 64(3), 410. https://doi.org/10.2967/jnumed.122.264677

Chicago Style (17th ed.) Citation

N, John, et al. "177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy." Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 64, no. 3 (2023): 410. https://doi.org/10.2967/jnumed.122.264677.

MLA (9th ed.) Citation

N, John, et al. "177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy." Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, vol. 64, no. 3, 2023, p. 410, https://doi.org/10.2967/jnumed.122.264677.